The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.
Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.
The Precision Peptide Company (PNGAF) launched a U.S. wholesale channel for its non-prescription products and began accepting business applications.
The program covers U.S.-made needle-free patches and supplements. Licensed American businesses that meet the company’s onboarding and compliance standards can apply, including gyms, clinics, med spas and retailers. Approved partners receive volume-based pricing, and orders ship from the company’s U.S. fulfillment operation. Prescription peptides remain available only through licensed prescribers via its telehealth pathway, not through wholesale.
The Precision Peptide Company (PNGAF) has become a strategic sponsor of Championing Mental Health 3, a professional boxing event promoted by Bash Boxing, scheduled for September 26, 2026 at Commerce Casino in Commerce, California, and set to be broadcast on UFC Fight Pass.
The Championing Mental Health series, founded by Anthony Girges of 555 Media Agency in partnership with Bash Boxing, focuses on mental health in boxing and has previously offered participating fighters one year of free therapy. Prior events have included a WBC Cruiserweight World Championship rematch headliner. The sponsorship aligns BPC’s peptide-based recovery and wellness products with combat sports athletes and fans and extends its existing combat sports marketing strategy with Mixed Martial Arts Group Limited. The company states it does not claim its products treat, cure or prevent any disease.
The Precision Peptide Company (PNGAF) will sponsor the 2026 Boulderthon running weekend on Sunday, September 27, 2026, in Boulder, Colorado.
As part of the sponsorship, the company plans an on-site booth at the outdoor Boulderthon Expo on Pearl Street Mall to showcase its U.S.-manufactured peptide wellness products to runners, families and spectators. Boulderthon’s 2025 event hosted over 15,600 runners, and organizers report more than 75 vendors at its expo. BPC links this sponsorship to its broader sports marketing strategy, which also includes a revenue-sharing marketing agreement with Mixed Martial Arts Group Limited.
The Precision Peptide Company (PNGAF) signed two short-term digital marketing and advertising agreements with Senergy Communications Capital and Komcore Capital in late August and early September 2026.
The Senergy agreement runs for one month from September 2, 2026, covering onboarding, ad account setup and social media management on Facebook, Instagram, TikTok and YouTube, for a fee of CAD$50,000 plus GST. The Komcore agreement starts August 31, 2026, has an initial 90-day term with possible renewal, focuses on social media engagement on X, Facebook, YouTube and Reddit, and pays Komcore CAD$55,000. Both counterparties operate at arm's length and report no current or intended interest in BPC securities.
The Precision Peptide Company (PNGAF) has advanced its Thymosin Alpha-1 (TA1) transdermal patch into formal testing in the United States as of September 8, 2026.
The current U.S.-based testing program is targeted for completion in Q3/Q4 2026, after which the company plans to move toward commercial production if results are satisfactory. TA1 is the second transdermal peptide in the portfolio after the BPC-157 patch and is being developed as a portable, needle-free alternative to traditional injectable TA1. The patch technology focuses on peptide stabilisation, skin permeation and sustained release, and is intended to complement BPC’s existing oral, topical, transdermal and telehealth-supported wellness offerings.
The Precision Peptide Company (PNGAF) authorized on July 31, 2026 the grant of restricted share units and incentive stock options under its omnibus share incentive plan.
The company granted 150,000 RSUs and 200,000 stock options to a consultant. Each option allows the purchase of one common share at an exercise price of $0.50 per share for a term of 10 years from the grant date. All RSUs and options are governed by the terms of the plan and applicable securities laws.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) will exhibit and sell its supplement range, led by The Recovery Patch, at FitExpo Anaheim on August 29–30, 2026 at the Anaheim Convention Center, booth 750. Attendees receive a 15% event discount on purchases.
The Recovery Patch is a needle-free transdermal BPC‑157 peptide patch, independently tested by Miraxis Labs at 95.5% chromatographic purity with a quantified 2.02 mg dose per patch. Precision Peptide will also showcase its oral and topical products, including BPC, KPV, Ageless, Chill, Blue capsules and Hair serum, all manufactured to cGMP standards and third‑party tested. A leadership team member will speak on peptides in biohacking during the Biohack Basics panel on August 29.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) announced the development of a tirzepatide-based needle-free transdermal patch in the United States as an addition to its peptide product lineup. The patch is designed to deliver tirzepatide through the skin, aiming to avoid injections and cold-chain storage.
According to The Precision Peptide Company, the patch is being developed with the goal of room-temperature stability and U.S.-based development and intended manufacturing in compliance with applicable regulatory requirements, including FDA standards. The company positions this program within a fast-growing GLP-1 market estimated at US$62–66 billion in 2025 and projected to reach US$185.3 billion by 2033, with Eli Lilly’s injectable tirzepatide products Mounjaro and Zepbound generating about US$36.5 billion in 2025 sales.
The company highlights barriers the patch is intended to address, including needle fear, refrigeration needs, sharps disposal, and real-world discontinuation of injectable GLP-1 therapy, while cautioning that market data are contextual and do not represent projections of its own future revenue or market share.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF)/b) has completed migrating the Amino Innovations online supplement store, its full product catalogue and existing customer base to the company’s own e-commerce platform at www.precisionpeptidecompany.com. Sales through the legacy Amino Innovations site have ceased, and all traffic now redirects to the company-owned storefront, where BPC manages the point of sale and customer relationship end to end.The migration consolidates a seven-product portfolio across six wellness categories—recovery, healthy aging, immune support, stress and sleep, hair, and cognitive support—into a single platform. According to The Precision Peptide Company, the moved customer base includes purchasers with transaction history and additional marketing leads, giving the company direct access to first-party data such as purchase history and communication preferences. BPC now controls the full commercial chain, from formulation and approved U.S. manufacturing through a single storefront, fulfillment process and compliance framework, serving customers across North America.
The Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) announced the introduction of the Peptide Pen, its second commercial product, expanding its U.S.-made peptide delivery platform beyond the existing BPC-157 transdermal patch.
The Peptide Pen is described as the first combined pen-and-vial peptide device with a 5mL dosing configuration, compared with commonly used 3mL cartridges, aiming to reduce cartridge changes and waste. It features an interchangeable cartridge system so customers can manage multiple peptide protocols with a single device.
According to the company, the Peptide Pen is designed, manufactured, and tested in the U.S. in a cGMP-certified (ISO 13485) facility, in partnership with Casetides. Product features include a mechanical click-dial for precision dosing, compatibility with 29G–32G needles, medical-grade ABS body, stainless steel drive, borosilicate glass cartridges, TSA-compliance, and a lifetime warranty. Commercial release is targeted for August 2026 via the company’s website.